DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival

Breast cancer patients with Luminal A disease generally have a good prognosis, but among this patient group are patients with good prognosis that are currently overtreated with adjuvant chemotherapy, and also patients that have a bad prognosis and should be given more aggressive treatment. There is...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischer, Thomas, Klajic, Jovana, Aure, Miriam Ragle, Louhimo, Riku, Pladsen, Arne V., Ottestad, Lars, Touleimat, Nizar, Laakso, Marko, Halvorsen, Ann Rita, Alnæs, Grethe I. Grenaker, Riis, Margit L.H., Helland, Åslaug, Hautaniemi, Sampsa, Lønning, Per Eystein, Naume, Bjørn, Børresen-Dale, Anne-Lise, Tost, Jörg, Kristensen, Vessela N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352035/
https://www.ncbi.nlm.nih.gov/pubmed/27911866
http://dx.doi.org/10.18632/oncotarget.13718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352035/
https://www.ncbi.nlm.nih.gov/pubmed/27911866
http://dx.doi.org/10.18632/oncotarget.13718

Ejemplares similares